Please fax both pages of completed form to your drug therapy team at 866.233.7151.
To reach your team, call toll-free 866.820.IVIG (866.820.4844).

Prescription & Enrollment Form
Subcutaneous immune globulin (SCIG)

accredo®

Four simple steps to submit your referral.

❑ Do not contact patient, benefits check only

1 Patient Information

Please attach copies of front and back of patient's insurance cards.

❑ New patient ❑ Current patient
Patient's first name _____ Last name _____ Middle initial _____
❑ Male ❑ Female Date of birth _____ Street address _____
Apt # _____ City _____ State _____ Zip _____
Parent/guardian (if applicable) _____ Phone _____
Patient's primary language: ❑ English ❑ Other If other, please specify _____

2 Prescriber Information

Prescriber's first name _____ Last name _____
Prescriber's title _____ If NP or PA, under direction of Dr. _____
Office contact and title _____ Street address _____
Suite # _____ City _____ State _____ Zip _____
Phone _____ Fax _____ NPI # _____ License # _____
Infusion location: ❑ Infusion clinic ❑ Office ❑ Patient's home
If infusion clinic, address: _____

3 Clinical Information

CHECK ONE

ICD-10 immunology: ❑ D80.0 Congenital Hypogam ❑ D83.9 CVID (unspecified) ❑ D81.9 SCID (unspecified)
ICD-10 neurology: ❑ G61.81 CIDP ❑ G61.82 MMN ❑ G35 MS (rel remit) ❑ G61.0 GBS ❑ G70.01 MG
ICD-10 rheumatology: ❑ M33.20 Polymyositis ❑ M33.90 Dermatomyositis
❑ **Other** _____

Other drugs used to treat the disease _____
Weight _____ kg/lbs Height _____ cm/in Date recorded _____
❑ NKDA ❑ Known drug allergies _____
Concurrent meds _____

4 Prescribing Information

Patient's first name _____ Last name _____ Middle initial _____ Date of birth _____
Prescriber's first name _____ Last name _____ Phone _____

Medication	Dose	Directions
❑ Cutaquig® 16.5% ❑ Cuvitru™ 20% ❑ Gammagard® liquid 10% ❑ Gammaked™ 10% ❑ Gamunex®-C 10% ❑ Hizentra® 20% prefilled syringe ❑ Hizentra® 20% vial ❑ Xembify® 20% ❑ _____	Infuse _____ gram(s) OR _____ mg per kg OR OR _____ grams per kg subcutaneously ❑ Once weekly ❑ Every 2 weeks ❑ Other frequency _____ (where clinically appropriate, round to the nearest vial size)	Infuse total dose of immune globulin subcutaneously in 1 to multiple sites via infusion pump as tolerated. Infusion rates per manufacturer recommendation as tolerated.
CHECK ONE ❑ HyQvia™ (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase 160 units per ml)* Total IG grams: _____ Infuse total grams per the ramp up schedule, then infuse total grams: ❑ **every 4 weeks**. ❑ **every 3 weeks**. Where clinically appropriate, round each dose to the nearest vial size.	Ramp up schedule: Treatment interval | 4 weeks | 3 weeks 1st infusion | 1st week | grams x 0.25 | grams x 0.33 2nd infusion | 2nd week | grams x 0.50 | grams x 0.67 3rd infusion | 4th week | grams x 0.75 | give total dose 4th infusion | 7th week | give total dose	Infuse Hyaluronidase subcutaneously in 1–2 sites at 1–2 mL per minute per site as tolerated. For each full or partial vial of immune globulin infused, administer the entire contents of the Hyaluronidase vial. Infuse total dose of immune globulin subcutaneously in 1–2 sites via infusion pump as tolerated. Infusion rates per manufacturer recommendation. Flush infusion line with 0.9% Normal Saline 10 mL as needed for full dose administration.

Premedication to be given 30 minutes prior to infusion: *(please strike through if not required)*
- Diphenhydramine 25 mg by mouth for mild infusion reactions, may increase to 50 mg for history of moderate to severe (contraindicated in patients with Myasthenia Gravis)
- Acetaminophen 650 mg by mouth

❑ Other _____

For patients weighing less than 60 kg, the following weight-based dosing range will be used: Acetaminophen: 10–15 mg/kg

For pediatric patients, the following weight- and age-based dosing range will be used:
≤9 kg and/or <2 years old: Diphenhydramine 1 mg/kg up to max of 6.25 mg
2–5 years old and >9 kg: Diphenhydramine 6.25 mg to 12.5 mg
6–12 years old: Diphenhydramine 12.5 to 25 mg

Medications to be used as needed: *(please strike through if not required)*
- Diphenhydramine 25 mg by mouth every 4–6 hours as needed for mild infusion reactions, may increase to 50 mg for moderate to severe; maximum of 4 doses per day (contraindicated in patients with Myasthenia Gravis)
- Lidocaine 4% applied topically to insertion site prior to needle insertion as needed to prevent site pain
- Acetaminophen 650 mg by mouth every 4–6 hours as needed for fever, headache or chills; maximum of 4 doses per day

Adverse reaction medications: *(keep on hand at all times)*
- Epinephrine 0.3 mg auto-injector 2-pk for patients weighing greater than or equal to 30 kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Epinephrine 0.15 mg auto-injector 2-pk for patients weighing less than 30 kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Diphenhydramine 25 mg by mouth for mild allergic reactions and 50 mg for moderate to severe

Supplies: *(please strike through if not required)*
Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

Quantity/Refills: Dispense 1 month supply. Refill x 1 year unless noted otherwise. ❑ Dispense 90 day supply. Refill x 1 year unless noted otherwise.
❑ Other _____

Accredo nursing services: *(please strike through if not required)*
Skilled nursing visits to educate patient on subcutaneous access, medication administration, use of supplies, therapy and disease state and to assess general status and response to therapy; patient discharged from nursing once teaching complete.

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

By signing below, I certify that the above therapy is medically necessary. I also authorize Accredo to initiate any de minimus authorization processes from applicable health plans, if needed, including the submission of any necessary forms to such health plans, to the extent not prohibited.

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE PHYSICIAN SIGNATURE REQUIRED

Date **Dispense as written** **Date** **Substitution allowed**

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

accredo®

accredo®

Prior authorization checklist
Primary immune deficiency disease (PIDD)

Providing Accredo with the documentation outlined in this checklist may increase the likelihood and speed of obtaining coverage for your patients with PIDD. Coverage criteria may vary by payer.

Referral form[1] (not required for electronic prescriptions)	
	Completed Immunoglobulin (Ig) referral form (available at **accredo.com**)
	Copies of the front and back of all medical insurance and prescription benefits cards
Clinical documents	
	History and Physical (H&P) and progress notes (within past 6 months) Note: H&P to include documented infection history/treatment
	Pre-treatment IgG, IgA, IgM, and Ig subclass serum levels (drawn on two different occasions when available) Current IgG, IgA, IgM, and Ig subclass serum levels
	Pre- and post-antigen testing (tetanus, pneumococcal polysaccharide or H Influenza type B) AND documentation of vaccine administration date

Medicare-approved PIDD diagnosis
D80 – Immunodeficiency with predominantly antibody defects
D80.0 – Hereditary hypogammaglobulinemia
D80.2 – Selective deficiency of immunoglobulin A (IgA)
D80.3 – Selective deficiency of immunoglobulin G (IgG) subclasses
D80.4 – Selective deficiency of immunoglobulin M (IgM)
D80.5 – Immunodeficiency with increased immunoglobulin M (IgM)
D80.6 – Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
D80.7 – Transient hypogammaglobulinemia of infancy
D81 – Combined immunodeficiencies
D81.0 – Severe combined immunodeficiency (SCID) with reticular dysgenesis
D81.1 – Severe combined immunodeficiency (SCID) with low T- and B-cell numbers
D81.2 – Severe combined immunodeficiency (SCID) with low or normal B-cell numbers
D81.5 – Purine nucleoside phosphorylase (PNP) deficiency
D81.6 – Major histocompatibility complex class I deficiency
D81.7 – Major histocompatibility complex class II deficiency
D81.89 – Other combined immunodeficiencies
D81.9 – Combined immunodeficiency, unspecified
D82 – Immunodeficiency associated with other major defects
D82.0 – Wiskott-Aldrich syndrome
D82.1 – Di George's syndrome
D82.4 – Hyperimmunoglobulin E (IgE) syndrome
D83 – Common variable immunodeficiency (CVID)
D83.0 – CVID with predominant abnormalities of B-cell numbers and function
D83.1 – CVID with predominant immunoregulatory T-cell disorders
D83.2 – CVID with autoantibodies to B- or T-cells
D83.8 – Other CVIDs
D83.9 – CVID, unspecified
G11.3 – Cerebellar ataxia with defective DNA repair

To receive in-home administration for intravenous immune globulin (IVIG) for the treatment of PIDD, Medicare Part B patients must be enrolled in the IVIG Demonstration initiative. For further information visit: **https://med.noridianmedicare.com/web/ivig**

Fax completed form to 866.233.7151.

If you have any questions, please call your Accredo Provider Support Advocate, or call 866.820.4844.

1. For referral forms visit accredo.com.

IGL-00090 AMC1018797 CED4738 CRP2009_004738.1

accredo®

Prior Authorization Checklist
Neuromuscular Disorders[1]

Providing Accredo with the documentation outlined in this checklist may increase the likelihood and speed of obtaining coverage for your patients. Coverage criteria many vary by payer.

Referral Form (not required for electronic prescriptions)	
	Completed Immunoglobulin (Ig) referral form (available at accredo.com)
	Copies of the front and back of all medical insurance and prescription benefits cards
Clinical Documents	
	History and Physical (H&P) and progress notes[2] (within past 6 months) Note: Diagnosis of the disorder must be unequivocal
	Documentation that other causes of demyelinating neuropathy have been excluded

Testing documentation:

- ☐ Electrophysiological motor-sensory nerve conductions
- ☐ Electromyography (EMG)
- ☐ Cerebrospinal fluid (CSF)
- ☐ Biopsy (muscle-nerve) - if necessary

Additional Requirements for Myasthenia Gravis	
	Tensilon test results
	Refractory to corticosteroids over a 6 month period documentation
	Ongoing Ig treatment must be documented in H&P and progress notes[2]
Additional Requirements for Polymyositis and Dermatomyositis Diagnosis	
	Creatine phosphokinase (CPK) values
	Electromyography (EMG) and/or muscle biopsy results

1 This Neuromuscular Disorders checklist is based on Medicare Part B guidelines related to Guillain-Barre' syndrome (GBS), relapsing-remitting multiple sclerosis, chronic inflammatory demyelinating polyneuropathy (CIDP) (and variant syndromes such as Multifocal Motor Neuropathy (MMN)), myasthenia gravis, refractory polymyositis, and refractory dermatomyositis polymyositis, and refractory dermatomyositis

2 Ongoing management and documentation requirements:
- Initial improvement and continued need must be meticulously documented in progress notes
- All weaning must be attempted and documented as either amount or frequency
- Must be a stoppage in IVIG if sustained improvement is noted with weaning or no improvement has taken place at all

Fax completed form to 866.233.7151.

If you have any questions, please call your Accredo Provider Support Advocate, or call 866.820.4844.

IGL-00091 CED4702 CRP2010_004702.1